Name: Binding of a drug to a target protein: Overcoming the limitations
Uploaded: 2016-11-11T00:00:00
Duration: 3 min 53 s
Description: Prof. Par Nordlund of the Karolinska Institutet tells us how the cellular thermal shift assay (CETSA) helps overcome the current limitations when accessing a drug’s binding of a target protein,

LabTube Meets

LabTube Meets at ELRIG 2016

ELRIG

Prof. Par Nordlund of the Karolinska Institutet tells us how the cellular thermal shift assay (CETSA) helps overcome the current limitations when accessing a drug’s binding of a target protein,

Binding of a drug to a target protein: Overcoming the limitations

Chas Bountra, Professor of Translational Medicine, Oxford Structural Genomics Consortium, University of Oxford, tells us more about the Structural Genomics Consortium and the work it is doing to make Oxford a major drug discovery centre.

Can you tell us more about the Structural Genomics Consortium?

Melanie Leveridge, Head, Screening Profiling and Mechanistic Biology, GSK, tells us about ELRIG, their vision, and how ELRIG events help to develop ideas and foster relationships.

ELRIG - Helping to develop ideas and foster relationships

Del Trezise, Conference Director for Drug Discovery 2016 talks about this year's meeting

ELRIG Drug Discovery 10 years and counting

Jon Moore, CSO at Horizon Discovery talks CRISPR-Cas9 and his experiences with technically demanding whole genome negative-selection screens. 

Identifying novel synthetic lethal targets with CRISPR-Cas9 

Jonathan Wingfield, Principal Scientist at AstraZeneca, talks AstraZeneca Open Innovation Portal and the use of acoustic mass spec for high-throughput screening. 

Mass spectrometry and high-throughput screening 

Andy Merritt of MRC Technology talks PAICS and its role in cancer

PAICS and its role in cancer

Steve Rees, VP, Screening Sciences and Sample Management at AstraZeneca describes the most pressing challenges and the importance of partnerships in drug discovery. 

Steve Rees talks drug discovery

Steve Rees, VP, Screening Sciences and Sample Management at AstraZeneca, talks partnerships and their importance in drug discovery.

The importance of partnerships in drug discovery

Jonathan Wingfield, Principal Scientist, AstraZeneca, describes some of the limitations of conventional mass spectrometry for high-throughput screening

The limitations of conventional mass spec for high-throughput screening

Vivian Li, Group Leader, The Francis Crick Institute, tell us about intestinal organoids and some of the features that make them attractive as research tools.

The role of intestinal organoids in tissue engineering

Vivian Li, Group Leader at the Francis Crick Institute describes the role organoids play in tissue engineering.

The role of organoids in tissue engineering

Jonathan Wingfield, Principal Scientist at AstraZeneca, describes how  acoustic mass spectrometry technology being used to screen biological targets.

The use of acoustic mass spec for screening biological targets

Kevin Doherty, Professor & MacLeod-Smith Chair of Biochemistry, University of Aberdeen tells us about some of the current limitations of current therapies for type 1 diabetes, and how his research is helping to address these issues.

Therapies for Type 1 Diabetes - Current Limitations and Novel Approaches

Vivian Li, Group Leader, The Francis Crick Institute, tells us about intestinal organoids and some of the features that make them attractive as research tools.

What are intestinal organoids?

Chas Bountra, Professor of Translational Medicine, Oxford Structural Genomics Consortium, University of Oxford, tells us about some of today's biggest drug discovery challenges.

What are some of the biggest challenges of drug discovery today?

We hear from the experts as they tell us their thoughts on the biggest challenges faced in drug discovery. 

What are the biggest challenges in drug discovery?

Prof Par Nordlund of the Karolinska Instituet discusses the limitations of current methods for accessing a drug’s binding of a target protein.<br/>

What are the limitations of current methods for accessing a drug’s binding of a target protein? 

Kevin Doherty, Professor & MacLeod-Smith Chair of Biochemistry, University of Aberdeen, tells us about some of the limitations of current therapies for type 1 diabetes.

What are the limitations of current therapies for type 1 diabetes?

Chas Bountra, Professor of Translational Medicine, Oxford Structural Genomics Consortium, University of Oxford, tells us about some of the improvements that can be made to the drug discovery process.

What can be done to improve the drug discovery process?

Jon Moore, CSO at Horizon Discovery, gives us his view of the 'essentialome'

Binding of a drug to a target protein: Overcoming the limitations

Posted by

ELRIG

1,936 views

|

November 11, 2016

LabTube Meets at ELRIG 2016

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.